Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

1.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

2.8K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.8K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

905
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
905
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

497
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
497
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

787
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
787
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

686
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
686

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myeloid cell renin-angiotensin-aldosterone system in hypertension and inflammation.

Current opinion in physiology·2026
Same author

3D EM uncovers mitochondrial network remodeling in residual triple negative breast cancer after conventional chemotherapy treatments.

iScience·2026
Same author

Central Nervous System T-cell immune architecture, and not HIV burden, tracks with cognition under long-term viral suppression.

PLoS pathogens·2026
Same author

Monocyte Oxidative Stress Underlies Persistent Immune Activation in Long COVID Postural Orthostatic Tachycardia Syndrome.

medRxiv : the preprint server for health sciences·2026
Same author

Aging Remodels Mitochondrial Architecture Across the Male Reproductive Axis.

Research square·2026
Same author

Factors associated with circulating levels of IL-17A in a high HIV-burden population.

Scientific reports·2026
Same journal

Targeting amino acid metabolism in hepatocellular carcinoma.

Trends in molecular medicine·2026
Same journal

Turning perfusion into repair through ferroptosis blockade.

Trends in molecular medicine·2026
Same journal

CaMKK2: A tumor stress-integration node.

Trends in molecular medicine·2026
Same journal

Precision gene editing: From proof-of-concept to curative therapies.

Trends in molecular medicine·2026
Same journal

Targeting ferroptosis halts graft deterioration in transplantation.

Trends in molecular medicine·2026
Same journal

Amyotrophic lateral sclerosis: A rare but aggressive adult-onset disease.

Trends in molecular medicine·2026
See all related articles

Related Experiment Video

Updated: Aug 5, 2025

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.7K

β2ARs: double edge sword in heart function.

Heather K Beasley1, Celestine N Wanjalla2, Annet Kirabo3

  • 1Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.

Trends in Molecular Medicine
|March 29, 2023
PubMed
Summary
This summary is machine-generated.

Understanding the dual role of beta2-adrenoceptor (β2AR) signaling is crucial for treating high-fat diet-induced heart failure, as its effects vary with context and activation level.

Keywords:
HFDheart failuremyocytemyofibroblastβ2 adrenoceptor

More Related Videos

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

2.9K
Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

20.3K

Related Experiment Videos

Last Updated: Aug 5, 2025

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.7K
Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

2.9K
Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

20.3K

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • High-fat diet (HFD) consumption is a major contributor to cardiovascular diseases, including heart failure.
  • The beta2-adrenoceptor (β2AR) is a key regulator of cardiac function, but its role in HFD-induced heart failure is complex.
  • Previous research suggests β2AR signaling can be both protective and detrimental in cardiac conditions.

Purpose of the Study:

  • To elucidate the context-dependent and activation-level-dependent roles of β2AR in the development of HFD-induced heart failure.
  • To highlight the significance of these findings for the development of targeted therapeutic strategies.

Main Methods:

  • The study likely involved animal models fed a high-fat diet to induce heart failure.
  • Pharmacological interventions or genetic manipulations targeting β2AR signaling were probably employed.
  • Cardiac function and molecular signaling pathways were assessed.

Main Results:

  • β2AR signaling exhibits divergent effects in HFD-induced heart failure, with context and activation level being critical determinants.
  • Specific signaling pathways activated by β2AR may mediate beneficial or detrimental outcomes.
  • The findings underscore the complexity of β2AR's contribution to cardiac pathophysiology.

Conclusions:

  • Understanding the nuanced roles of β2AR is essential for designing effective and safe therapies for HFD-induced heart failure.
  • Targeting β2AR requires careful consideration of its specific signaling context to avoid adverse effects.
  • Further research into β2AR modulation could lead to novel therapeutic approaches for metabolic heart disease.